WHAT IS CLAIMED IS:

1. A compound of the formula:

$$[ARB(NEPi)](Cat)_{1-3} \cdot x\ H_2O$$

wherein
ARB is S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form;
NEPi is 5-biphenyl-4yl-5-(3-carboxy-propionylamino)-2-methyl-pentanoic acid in the anion form;
(Cat) is a cation; and
x is 0 to 3.

2. The compound of claim 1 wherein (Cat) is a monovalent cation.

3. The compound of claim 1 wherein (Cat) is a monovalent cation selected from the group consisting of Na, K and NH_4.

4. The compound of claim 1 wherein (Cat) is Na.

5. The compound of claim 1 wherein x is 1 to 3.

6. The compound of claim 1 wherein x is 2.5

7. The compound of claim 1 wherein x is 1 to 3 and (Cat) is Na.

8. The compound of claim 1 wherein [ARB(NEPi)] is 3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl{2"-(tetrazol-5-ylate)biphenyl-4'ylmethyl}amino)butyrate.

9. The compound of claim 1 wherein $(Cat)_{1-3}$ is Na_3.

10. The compound of claim 1 wherein the compound has the sum formula $C_{48}H_{55}N_6O_8Na_3 \cdot 2.5\ H_2O$.

11. A pharmaceutical composition comprising an effective amount of the compound of any of claims 1 to 10 and at least one pharmaceutically acceptable additive.

12. The pharmaceutical composition of claim 11 wherein the pharmaceutically acceptable additive is selected from the group consisting of diluents or fillers, disintegrants, glidants, lubricants, binders, colorants and combinations thereof.

13. Trisodium [3-((1*S*,3*R*)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(*S*)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate.

14. A pharmaceutical composition comprising an effective amount of the compound of claim 13 and at least one pharmaceutically acceptable additive.

15. The pharmaceutical composition of claim 14 wherein the pharmaceutically acceptable additive is selected from the group consisting of diluents or fillers, disintegrants, glidants, lubricants, binders, colorants and combinations thereof.

CLAIMS

1. Trisodium [3-((1*S*,3*R*)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(*S*)-3'-methyl-2'-(pentanoyl{2''-(tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyrate] hemipentahydrate in the crystalline form.

2. The compound of claim 1 having an asymmetric unit comprising six $C_{48}H_{55}N_6O_8Na_3 \cdot 2.5\ H_2O$ formula units.

3. The compound of claims 1 or 2 characterized by an Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectrum having the following absorption bands expressed in reciprocal wave numbers (cm^{-1})(± 2 cm^{-1}):
1711 (st), 1637 (st), 1597 (st), 1401 (st).

4. The compound of claim 3 characterized by an Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR) spectrum having the following absorption bands expressed in reciprocal wave numbers (cm^{-1})(± 2 cm^{-1}):
2956 (w), 1711 (st), 1637 (st), 1597 (st), 1488 (w), 1459 (m), 1401 (st), 1357 (w), 1295 (m), 1266 (m), 1176 (w), 1085 (m), 1010 (w), 1942 (w), 907 (w), 862 (w), 763 (st), 742 (m), 698 (m), 533 (st).

5. The compound of any of claims 1 to 4 characterized by an X-ray powder diffraction pattern taken with a Scintag XDS2000 powder diffractometer comprising the following interlattice plane intervals:
d in [Å] (± 0.1 Å): 21.2(s), 17.0(w), 7.1(s), 5.2(w), 4.7(w), 4.6(w), 4.2(w), 3.5(w), 3.3(w).

6. A pharmaceutical composition comprising

(a) the compound according to any of claims 1 to 5; and

(b) at least one pharmaceutically acceptable additive.

7. The pharmaceutical composition of claim 6, wherein the pharmaceutically acceptable additive is selected from the group consisting of diluents or fillers, disintegrants, glidants, lubricants, binders, colorants and combinations thereof.

8. A method of preparing the dual-acting compound according to any of claims 1 to 5, said method comprising the steps of:

(i) dissolving (*S*)-*N*-valeryl-*N*-{[2'-(1*H*-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2*R*,4*S*)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in a suitable solvent;

(ii) dissolving a basic compound of Na in a suitable solvent;

(iii) combining the solutions obtained in steps (i) and (ii);

(iv) precipitation of the solid, and drying same to obtain the dual-acting compound; or alternatively

obtaining the dual-acting compound by exchanging the solvent(s) employed in steps (i) and (ii) by

(iva) evaporating the resulting solution to dryness;

(va) re-dissolving the solid in a suitable solvent;

(via) precipitation of the solid and drying same to obtain the dual-acting compound.

9. The method of claim 8 wherein the suitable solvent in steps (i) and/or (va) is acetone.

10. The method of claim 8 or 9, wherein the basic compound of Na is NaOH, Na_2CO_3, $NaHCO_3$, NaOMe, NaOAc or NaOCHO.

11. Use of a compound according to any of claims 1 to 5 for the manufacture of a medicament for the treating or prevention of a condition or disease selected from the group consisting of hypertension, heart failure (acute and chronic), congestive heart failure, left ventricular dysfunction, hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, renal vascular hypertension, diabetic retinopathy, migraine, peripheral vascular disease, Raynaud's disease, luminal hyperplasia, cognitive dysfunction, glaucoma and stroke.

12. Use according to claim 11, wherein the condition or disease is hypertension.

13. A pharmaceutical composition comprising

(a) the compound according to any one of claims 1 to 5;

(b) a therapeutic agent selected from an anti-diabetic, a hypolipidemic agent, an anti-obesity agent and an anti-hypertensive agent; and

(c) at least one pharmaceutically acceptable additive.

14. The pharmaceutical composition according to claim 13 wherein the therapeutic agent is amlodipine besylate.

15. The pharmaceutical composition according to claim 13, wherein the therapeutic agent is hydrochlorothiazide.

16. Use according to claim 11, wherein the condition or disease is heart failure (acute and chronic).